Literature DB >> 7519242

Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.

J Kim1, M Namchuk, T Bugawan, Q Fu, M Jaffe, Y Shi, H J Aanstoot, C W Turck, H Erlich, V Lennon, S Baekkeskov.   

Abstract

The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD65) is a major autoantigen in two human diseases that affect its principal sites of expression. Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD65. Anti-GAD65 autoantibodies in IDDM are predominantly directed to conformational epitopes. Here we report the characterization of humoral autoimmune responses to GAD65 in 35 SMS patients, of whom 13 (37%) also had IDDM. All SMS patients immunoprecipitated native GAD65 and the main titers were orders of magnitude higher than in IDDM patients. Furthermore, in contrast to the situation in IDDM, autoantibodies in 35 of 35 (100%) of SMS patients recognized denatured GAD65 on Western blots. Two major patterns of epitope specificity were identified on Western blots. The first pattern, detected in 25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with a linear NH2-terminal epitope residing in the first eight amino acids of GAD65. Nine of nine individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype and HLA-DR3, DQw2 was particularly abundant. The second pattern, detected in 10 of 35 patients (29%) of whom two had IDDM (20%), included reactivity with the NH2-terminal epitope plus strong reactivity with one or more additional epitope(s) residing COOH-terminal to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD65 molecule, but may also include some cases of epitope recognition associated with IDDM resistant HLA-haplotypes. The principal NH2-terminal linear epitope in GAD65 distinguishes the reactivity of SMS and IDDM autoantibodies and may be a determinant of pathogenicity for GABA-ergic neurons. The greater magnitude and distinct specificity of the humoral response to GAD65 in SMS may reflect a biased involvement of the T helper cell type 2 (Th2) subset of CD4+ T cells and antibody responses, whereas IDDM is likely mediated by the Th1 subset of CD4+ T cells and cytotoxic T cell responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519242      PMCID: PMC2191592          DOI: 10.1084/jem.180.2.595

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

Review 1.  An overview on possible mechanisms of destruction of the insulin-producing beta cell.

Authors:  A Cooke
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase.

Authors:  Y C Chang; D I Gottlieb
Journal:  J Neurosci       Date:  1988-06       Impact factor: 6.167

3.  Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

Authors:  W Richter; Y Shi; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 4.  Stiff-man syndrome updated.

Authors:  T R Lorish; G Thorsteinsson; F M Howard
Journal:  Mayo Clin Proc       Date:  1989-06       Impact factor: 7.616

5.  Pancreatic beta cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble.

Authors:  S Christgau; H Schierbeck; H J Aanstoot; L Aagaard; K Begley; H Kofod; K Hejnaes; S Baekkeskov
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

6.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

7.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.

Authors:  S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

8.  Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase.

Authors:  W A Hagopian; B Michelsen; A E Karlsen; F Larsen; A Moody; C E Grubin; R Rowe; J Petersen; R McEvoy; A Lernmark
Journal:  Diabetes       Date:  1993-04       Impact factor: 9.461

9.  Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets.

Authors:  J Kim; W Richter; H J Aanstoot; Y Shi; Q Fu; R Rajotte; G Warnock; S Baekkeskov
Journal:  Diabetes       Date:  1993-12       Impact factor: 9.461

10.  Monoclonal antibodies to glutamic acid decarboxylase.

Authors:  D I Gottlieb; Y C Chang; J E Schwob
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  43 in total

1.  Cerebellar degeneration and polyglandular autoimmune syndrome with anti-glutamic acid decarboxylase antibodies.

Authors:  S Rüegg; M Stahl; M Bühlmann; A Dupont; P A Lyrer; R L Humbel; A J Steck
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

2.  Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.

Authors:  L Hermitte; N Martin-Moutot; J Boucraut; R Barone; C Atlan-Gepner; M Seagar; J Pouget; J P Kleisbauer; F Couraud; B Vialettes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 3.  Autoimmune diabetes: more than just one flavor?

Authors:  H K Chiu; J P Palmer
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 4.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

5.  Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies.

Authors:  Esther Ganelin-Cohen; Dalit Modan-Moses; Rina Hemi; Hannah Kanety; Bruria Ben-Zeev; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2015-12-29       Impact factor: 4.866

6.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

7.  Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein.

Authors:  Jordan Steed; Lisa K Gilliam; Robert A Harris; Ake Lernmark; Christiane S Hampe
Journal:  J Immunol Methods       Date:  2008-03-07       Impact factor: 2.303

8.  Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.

Authors:  B Ziegler; M Schlosser; F Lühder; M Strebelow; P Augstein; W Northemann; A C Powers; M Ziegler
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

9.  New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin.

Authors:  Michael Marnane; Aangela Vincent; Michael Hutchinson
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

10.  Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil.

Authors:  Shiv Saidha; S Murphy; A Ronayne; P McCarthy; M J Hennessy; T Counihan
Journal:  J Neurol       Date:  2010-02-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.